上海医药最新公告：盐酸曲马多注射液通过仿制药一致性评价

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has passed the consistency evaluation for Tramadol Hydrochloride Injection, which is primarily used for treating moderate to severe pain [1] Summary by Categories Product Development - The company has invested approximately RMB 1.52 million in the research and development of this drug for the consistency evaluation [1] Market Impact - Products that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, which is expected to help expand the market share of this drug and enhance its market competitiveness [1] Risks and Uncertainties - There is a possibility that the sales of this drug may not meet expectations, indicating significant uncertainty regarding its market performance [1]